Literature DB >> 18330527

[Lifestyle drugs in medicine].

Wolfgang Harth1, Kurt Seikowski, Barbara Hermes, Uwe Gieler.   

Abstract

Lifestyle drugs have become an important new group of medications, which are taken by healthy people to increase the individual well-being and quality of life. Nootropics, psychopharmaceuticals, hormones and "ecodrugs" are today the main groups. The wish for eternal youth, beauty and potency is central, and lifestyle medications are also requested to influence cosmetic findings, which are usually simply a result of the natural aging process. Lifestyle drugs seem to be harmless, but the physician must pay attention to possible abuse, side effects, risks and complications. Additionally, however, lifestyle drugs are also frequently used by patients suffering from emotional disorders such as somatoform disorders. Medicalization of physiological life is then expected to solve psychosocial problems, but without success. The use of lifestyle medications in somatoform disorders is contraindicated and psychotherapy or psychopharmacological treatment come first. With this overview article, we would like to make an update of new lifestyle drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18330527     DOI: 10.1007/s10354-007-0473-z

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  37 in total

1.  [Surfing the Internet with side effects: problems surrounding smart drugs].

Authors:  J M Hesselink
Journal:  Dtsch Med Wochenschr       Date:  1999-06-04       Impact factor: 0.628

Review 2.  Lifestyle medicines.

Authors:  D Gilbert; T Walley; B New
Journal:  BMJ       Date:  2000-11-25

3.  The diagnosis and management of benzodiazepine dependence.

Authors:  Heather Ashton
Journal:  Curr Opin Psychiatry       Date:  2005-05       Impact factor: 4.741

4.  The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.

Authors:  Elise A Olsen; Maria Hordinsky; David Whiting; Dow Stough; Stuart Hobbs; Melissa L Ellis; Timothy Wilson; Roger S Rittmaster
Journal:  J Am Acad Dermatol       Date:  2006-12       Impact factor: 11.527

5.  Getting an edge--use of stimulants and antidepressants in college.

Authors:  Richard Kadison
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

6.  Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male, 9-12 February 2006, Salzburg, Austria.

Authors:  A Morales; E Nieschlag; M Schubert; A A Yassin; M Zitzmann; M Oettel
Journal:  Aging Male       Date:  2006-12       Impact factor: 5.892

7.  An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.

Authors:  Lisa E Diamond; Dennis C Earle; Julia R Heiman; Raymond C Rosen; Michael A Perelman; Ronald Harning
Journal:  J Sex Med       Date:  2006-07       Impact factor: 3.802

8.  Medically unexplained cutaneous sensory symptoms may represent somatoform dissociation: an empirical study.

Authors:  Madhulika A Gupta; Aditya K Gupta
Journal:  J Psychosom Res       Date:  2006-02       Impact factor: 3.006

9.  [Somatization of erectile disorders by the introduction of sildenafil].

Authors:  M W Hengeveld
Journal:  Ned Tijdschr Geneeskd       Date:  1998-10-24

10.  Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction--an open, randomized cross-over study with flexible dosing.

Authors:  Harmut Porst; Hermann M Behre; Andreas Jungwirth; Martin Burkart
Journal:  Eur J Med Res       Date:  2007-02-26       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.